Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study

Table 1 Drugs used to construct test set for docking with their proposed HLA-association

Generic name	Brand name	DBID	Indication	ADR	HLA
Abacavir	Zaigen	DB01048	HIV antiviral	Hypersensitivity	B*57:01
Allopurinol	Zyloprim	DB00437	Uric acid inhibitor	SCAR	B*58:01
Atorvastatin	Lipitor	DB01076	High cholesterol	Hypercholesterolemia cardiac heart disease	DRB1*10:10^a
Carbamazepine	Tegretol	DB00564	Seizures bipolar disorder	SJS/TEN	B*15:02
Ciprofloxacin	Cipro	DB00537	Antibiotic	Gastrointestinal irritation	B*50:02^a
Clozapine	Clozaril	DB00363	Antipsychotic	Agranulocytosis	DRB5*02:01
Fenofibrate	Tricor	DB01039	High cholesterol	Acute Generalized Exanthematous Pustutosis (AGEP)	A*33:01^a
Flucloxacillin	Floxapen	DB00301	Antibiotic	DILI	B*57:01
Methyldopa	Aldomet	DB00968	Anti-hypertensive	N/A	A*33:01^a
Minocycline	Minocin	DB01017	Antimicrobial	Thyroid hyperplasia	B*35:02^a
Pazopanib	Votrient	DB06589	Chemotherapy	DILI ALT concentration increase	B*57:01
Sertraline	Zoloft	DB01104	PTSD/OCD	Serotonin syndrome	A*33:01^a
Simvastatin	Zocor	DB00641	High cholesterol	Myalgia arthralgia	B*13:02^a
Ticlopidine	Ticlid	DB00208	Thrombotic stroke	Agranulocytosis aplastic anemia neutropemia	A*33:01

ISSN: 1758-2946